In summary, the demographics, tumor characteristics and treatment regimens were highly comparable in the two cohorts, except for the higher proportion of patients with PD-L1≧ 1% in the training cohort (80.2% vs. 64.8%) compared to the validation cohort. Here, CD274 is linked to neoplasm.